Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)

DOI: 10.1080/2162402X.2018.1428158

Keywords: anti-CD20, CLL, Fc receptors, obinutuzumab, rituximab

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text